Vahakn Shahinian
Overview
Explore the profile of Vahakn Shahinian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
2412
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schaub J, Oerline M, Crivelli J, Maalouf N, Best S, Asplin J, et al.
Kidney360
. 2025 Feb;
PMID: 39918878
Background: Emerging data suggest sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA) may lower stone risk. Methods: We characterized 24-hour urine parameters among individuals with kidney stone disease...
2.
Hsi R, Yan P, Maalouf N, Best S, Asplin J, Shahinian V, et al.
JAMA Netw Open
. 2024 Aug;
7(8):e2428953.
PMID: 39172453
No abstract available.
3.
Caram M, Kumbier K, Tsao P, Burns J, Sparks J, Stensland K, et al.
Cancer Med
. 2024 Aug;
13(12):e7334.
PMID: 39143030
Introduction: Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with prognoses varying from months to years at time of castration-resistant diagnosis. Optimal first-line therapy for those with different prognoses...
4.
Skolarus T, Hawley S, Forman J, Sales A, Sparks J, Metreger T, et al.
Implement Sci Commun
. 2024 Apr;
5(1):37.
PMID: 38594740
Background: Many men with prostate cancer will be exposed to androgen deprivation therapy (ADT). While evidence-based ADT use is common, ADT is also used in cases with no or limited...
5.
Cao J, Zhang X, Shahinian V, Yin H, Steffick D, Saran R, et al.
Nat Mach Intell
. 2023 Dec;
4(12):1121-1129.
PMID: 38148789
Delays in the identification of acute kidney injury (AKI) in hospitalized patients are a major barrier to the development of effective interventions to treat AKI. A recent study by Tomasev...
6.
Hsi R, Crivelli J, Yan P, Shahinian V, Hollingsworth J
Urol Pract
. 2023 Dec;
11(1):172-178.
PMID: 38117963
Introduction: Clinical guidelines recommend monitoring for metabolic derangements while on preventive pharmacologic therapy for kidney stone disease. The study objective was to compare the frequency of side effects among patients...
7.
Pockros B, Stensland K, Shahinian V
Urol Pract
. 2023 Sep;
10(6):537-539.
PMID: 37754065
No abstract available.
8.
Crivelli J, Yan P, Shahinian V, Hsi R, Hollingsworth J
Urol Pract
. 2023 Jun;
10(4):400-406.
PMID: 37341368
Introduction: The AUA Medical Management of Kidney Stones guideline outlines recommendations on follow-up testing for patients prescribed preventive pharmacological therapy. We evaluated adherence to these recommendations by provider specialty. Methods:...
9.
Zhang Z, Modi P, Shahinian V, Herrel L, Dupree J, Yan P, et al.
Urol Pract
. 2023 Jun;
7(3):182-187.
PMID: 37317461
Introduction: We compared cumulative reimbursement to urologists following implementation of surveillance vs immediate treatment. Active surveillance for prostate cancer is widely considered beneficial and cost-effective for low risk patients, although...
10.
Skolarus T, Forman J, Sparks J, Metreger T, Hawley S, Caram M, et al.
Implement Sci Commun
. 2023 Mar;
4(1):31.
PMID: 36941664
No abstract available.